INTECHOPEN
IntechOpen, the first native scientific publisher of Open Access books, announced today that Anke Beck, PhD, will join the company as incoming CEO. Dr. Beck joins IntechOpen with 20 years of publishing industry experience, most recently at De Gruyter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180325005110/en/
“As scientists, we’ve lead IntechOpen’s growth to its current leading position in the Open Access Books market, and now, we are excited to join forces with Dr. Beck who, no doubt, will have an impact on our further expansion”, said Alex Lazinica, IntechOpen’s co-founder and CEO. “I am confident that Dr. Beck’s deep understanding of international scholarly communications, superb reputation and trusted relationships with academics, institutions and funders will augment our business and open new business approaches as we strive to answer the scientific community’s publishing needs.”
As a Managing Director at De Gruyter, a Berlin-based scholarly publisher, Dr. Beck drove Open Access publishing successfully with a foresight into the market. She led De Gruyter into a prominent position in the competitive Open Access market globally.
“I am thrilled about the opportunity to join IntechOpen which combines innovative and agile technology, custom-fit marketing with the 21st century’s scientific needs,” Dr. Beck said. “IntechOpen’s commitment to scholarly communications quality and access is a perfect solution required to face the market challenges. I am convinced that jointly we can manifest our leading market position, expand our geographic reach, extend the publishing scope, to act in line of the academic R&D community.”
IntechOpen is the market leader in scientific publishing of Open Access books with more than 114 million downloads of chapters and books to date. More than 100,000 researchers, including Nobel Prize laureates, have published their research on the platform.
About IntechOpen
Founded in 2004, IntechOpen, the first native scientific publisher of Open Access books, provides a collaborative environment for peer-reviewed scholarly content and book publishing of academic research, giving scientific thinking its home. The scientific community of editors, authors, funders and librarians worldwide benefit from open access research dissemination, ensuring faster spreading and advancement of scientific knowledge. The company’s global headquarter is in London, UK. www.intechopen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180325005110/en/
Contact:
IntechOpen
US:
Andy Ybarra, +1 651-338-9797
Andy.Ybarra@creation.io
or
UK:
Andy
Rohr, +44 (0)
20 7067 0276
Andy.Rohr@creation.io
or
Croatia:
Natalia
Reinic, +385 (0) 91-5638 157
reinic@intechopen.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom